

**Strides Pharma Canada Inc.**  
**Balance Sheet as at March 31, 2024**

		Amount in CAD	
	Note No.	31-Mar-24	31-Mar-23
<b>A ASSETS</b>			
<b>I Non-current assets</b>			
(a) Property, plant and equipment		-	603
(b) Other intangible assets		618,469	854,272
(c) Intangibles assets under development			1,582,183
(d) Financial assets			
(i) Investments	1	3,803,195	3,803,195
<b>Total non-current assets</b>		<b>4,421,664</b>	<b>6,240,253</b>
<b>II Current assets</b>			
(a) Inventories		-	172,061
(b) Financial assets			
(i) Trade receivables	2	347,429	462,456
(ii) Cash and cash equivalents	3	77,639	45,990
(c) Other Current Assets	4	816,787	2,969,705
<b>Total current assets</b>		<b>1,241,855</b>	<b>3,650,212</b>
<b>TOTAL ASSETS</b>		<b>5,663,519</b>	<b>9,890,465</b>
<b>B EQUITY AND LIABILITIES</b>			
<b>I Equity</b>			
(a) Equity share capital	5	1,000	1,000
(b) Reserves and Surplus	6	(4,863,552)	7,017,380
<b>Total Equity</b>		<b>5,091,712</b>	<b>7,018,380</b>
<b>II Liabilities</b>			
<b>1 Current liabilities</b>			
(a) Financial liabilities			
(i) Trade payables	7	541,069	309,046
(ii) Other financial liabilities	8	16,514	2,172,895
(b) Other current liabilities		-	
(c) Provisions	9	14,223	390,144
<b>Total current liabilities</b>		<b>571,807</b>	<b>2,872,085</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>5,663,519</b>	<b>9,890,465</b>

**Strides Pharma Canada Inc.**  
**Statement of Profit And Loss for the Year Ended March 31, 2024**

Particulars	Note No.	Amount in CAD	
		31-Mar-24	31-Mar-23
<b>1</b> Revenue from operations	10	1,415,126	867,679
<b>2</b> Other Income	11	90,299	49,893
<b>3 Total Revenue (1+2)</b>		<b>1,505,425</b>	<b>917,572</b>
<b>4 Expenses</b>			
(a) Cost of goods sold		533,071	1,321,374
(b) Employee benefits expense	12	579,295	66,521
(c) Finance costs	13	4,634	3,436
(d) Depreciation and amortisation expense		1,818,589	237,460
(e) Other expenses	14	496,503	796,608
<b>Total expenses</b>		<b>3,432,092</b>	<b>2,425,398</b>
<b>5 Profit / (Loss) before exceptional items and taxes (3-4)</b>		<b>(1,926,667)</b>	<b>(1,507,826)</b>
<b>6</b> Exceptional Item		-	-
<b>7 Profit / (Loss) before taxes (5+6)</b>		<b>(1,926,667)</b>	<b>(1,507,826)</b>
<b>8 Tax Expense:</b>			
(1) Current tax		-	-
(2) Deferred tax		-	-
Total tax expenses		-	-
<b>9 Profit / (Loss) for the year after tax</b>		<b>(1,926,667)</b>	<b>(1,507,826)</b>

**STRIDES PHARMA CANADA INC.**  
**Statement of changes in Equity**  
**FOR THE YEAR ENDED MARCH 31, 2024**

**(A) Equity share capital**

Particulars	Amount in CAD
<b>Balance as at March 31, 2023</b>	<b>1,000</b>
Changes in equity share capital during the year	-
<b>Balance as at March 31, 2024</b>	<b>1,000</b>

**(B) Other equity**

Particulars	Share application money pending allotment	Reserves and surplus	Total
		Retained earnings	
<b>Balance as at March 31, 2023</b>	<b>9,954,265</b>	<b>(2,936,885)</b>	<b>7,017,380</b>
Application money received during the year	-	-	-
Profit/loss for the year	-	(1,926,667)	(1,926,667)
<b>Balance as at March 31, 2024</b>	<b>9,954,265</b>	<b>(4,863,552)</b>	<b>5,090,712</b>

Strides Pharma Canada Inc.  
Notes forming part of financial statement

Note No.

1 Non current investments		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Pharmapar Inc	3,803,195	3,803,195	
<b>Total</b>	<b>3,803,195</b>	<b>3,803,195</b>	

  

2 Trade receivables		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
<b>Unsecured</b>			
Considered good	347,429	462,456	
<b>Total</b>	<b>347,429</b>	<b>462,456</b>	

  

3 Cash and cash equivalents		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Balances with banks:			
In current accounts	77,639	45,990	
<b>Total</b>	<b>77,639</b>	<b>45,990</b>	

  

4 Other current assets		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
<b>Unsecured, considered good</b>			
Loans and advances to Group entities	684,896	2,881,716	
Balances with government authorities:			
- GST receivable	129,831	86,788	
Prepaid expenses	2,059	1,201	
<b>Total</b>	<b>816,787</b>	<b>2,969,705</b>	

  

5 Share capital		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Issued, subscribed and fully paid-up			
Equity share capital	1,000	1,000	
<b>Total</b>	<b>1,000</b>	<b>1,000</b>	

  

6 Reserves and surplus		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Share Application money Pending Allotment	9,954,265	7,839,265	
Add: Addition during the year	-	2,115,000	
<b>Share Application money Pending Allotment</b>	<b>9,954,265</b>	<b>9,954,265</b>	
<b>Surplus in statement of profit and loss</b>			
Opening balance	(2,936,885)	(1,429,059)	
Add: Profit / (Loss) for the year	(1,926,667)	(1,507,826)	
<b>Closing balance</b>	<b>(4,863,552)</b>	<b>(2,936,885)</b>	
<b>Total</b>	<b>5,090,712</b>	<b>7,017,380</b>	

  

7 Trade payables		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Trade payable	541,069	309,046	
<b>Total</b>	<b>541,069</b>	<b>309,046.34</b>	

  

8 Other Current financial Liabilities		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Payable to group entities		2,177,205	
Payable to employee (salary)	(9,474)		
Other payables:			
- Statutory remittances	25,988	(4,310)	
<b>Total</b>	<b>16,514</b>	<b>2,172,895</b>	

**Strides Pharma Canada Inc.**  
**Notes forming part of financial statement**

**Note No.**

9 Provisions	Amount in CAD	
	Particulars	
	31-Mar-24	31-Mar-23
Provision for expenses	14,223	390,144
<b>Total</b>	<b>14,223</b>	<b>390,144</b>

10 Revenue from operations	Amount in CAD	
	Particulars	
	31-Mar-24	31-Mar-23
Sale of product and services	1,415,126	867,679
<b>Total</b>	<b>1,415,126</b>	<b>867,679</b>

11 Other Income	Amount in CAD	
	Particulars	
	31-Mar-24	31-Mar-23
Profit on sale of investment		
Sundry balance written back	-	9
Exchange fluctuation gain - Not realized	44,515	-
Interest income	45,783	49,883
<b>Total</b>	<b>90,299</b>	<b>49,893</b>

12 Employee benefit expenses	Amount in CAD	
	Particulars	
	31-Mar-24	31-Mar-23
Salaries and wages	579,295	66,521
<b>Total</b>	<b>579,295</b>	<b>66,521</b>

13 Finance cost	Amount in CAD	
	Particulars	
	31-Mar-24	31-Mar-23
Finance Cost	4,634	3,436
<b>Total</b>	<b>4,634</b>	<b>3,436</b>

14 Other expenses	Amount in CAD	
	Particulars	
	31-Mar-24	31-Mar-23
Consumables	41,733	20,692
Coverison & processing charges	16,944	110,000
Commission	-	32
Rates & taxes	290,224	310,972
Repairs & Maintenance	306	4,811
Courier Charges	386	-
Insurance	12,759	1,205
Conveyance & Travelling	-	340
Advertising & selling expenses	-	5,175
General expenses	3,333	7,306
Printing & stationery	1,201	-
Director Sitting Fess	7,000	7,000
Net loss on foreign currency transactions	-	62,275
Professional fees & Legal fees	93,738	246,453
Provision for doubtful debts	28,880	-
Miscellaneous Expense	-	20,347
<b>Total</b>	<b>496,503</b>	<b>796,608</b>